Jan Balzarini
About
In The Last Decade
Jan Balzarini
504 papers receiving 11.3k citations
Hit Papers
Peers
Comparison fields: 5 of 139
- Organic Chemistry 5.7k
- Molecular Biology 4.4k
- Infectious Diseases 2.7k
- Epidemiology 1.7k
- Virology 1.5k
Countries citing papers authored by Jan Balzarini
This map shows the geographic impact of Jan Balzarini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Balzarini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Balzarini more than expected).
Fields of papers citing papers by Jan Balzarini
This network shows the impact of papers produced by Jan Balzarini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Balzarini. The network helps show where Jan Balzarini may publish in the future.
Co-authorship network of co-authors of Jan Balzarini
This figure shows the co-authorship network connecting the top 25 collaborators of Jan Balzarini. A scholar is included among the top collaborators of Jan Balzarini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Balzarini. Jan Balzarini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 13 | |
| 2 | 18 | |
| 3 | 34 | |
| 4 | Chemotherapy of human immunodeficiency virus by pradimicin A: a novel therapeutic concept for treatment of glycosylated enveloped viruses | 2 |
| 5 | Activity of different classes of nucleoside and nucleotide analogues against adenovirus in cell culture | 1 |
| 6 | 9 | |
| 7 | “Lock-in” modified cycloSal-D4TMP and BVDUMP triesters – extension of a pronucleotide system | 1 |
| 8 | Synthesis and biological evaluation of bicyclic furano pyrimidine nucleosides as inhibitors of human cytomegalovirus | 2 |
| 9 | New bicyclic nucleoside analogues (BCNAs) show selective and specific activity against human cytomegalovirus (HCMV) | 1 |
| 10 | Mannose-specific plant lectins may qualify as efficient microbicides against human immunodeficiency virus transmission | 1 |
| 11 | Anti-varicella-zoster virus bicyclic nucleosides: Synthesis and in vitro evaluation of 2 ',3 '-dideoxy nucleoside derivatives | 1 |
| 12 | Susceptibilities of several drug-resistant varicella-zoster virus (VZV) strains to bicyclic pyrimidine nucleoside analogues (BCNAs) | 3 |
| 13 | Early restaging positron emmision tomography (PET) with 18F-fluorodeoxyglucose ((18)FDG) predicts outcome in patients with aggressive non Hodgkin's lymphoma (NHL). | 3 |
| 14 | 2 | |
| 15 | Therapeutic potential of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) as an antiviral drug | 4 |
| 16 | 2',3'-Dideoxynucleoside analogues as anti-HIV agents | 6 |
| 17 | Acyclic and carbocyclic nucleoside analogues as inhibitors of HIV replication | 3 |
| 18 | 2',3'-Dideoxynucleoside analogues as inhibitors of human immunodeficiency virus | 1 |
| 19 | Arabinosyl-5-azacytosine: mechanisms of native and acquired resistance. | 17 |
| 20 | Synthesis and biological activity of 3'-azido- and 3'-amino substituted nucleoside analogs | 15 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.